Results 1 to 10 of about 3,092 (212)

Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins. [PDF]

Cell Reports, 2020
Botulinum neurotoxin (BoNT) is one of the most acutely lethal toxins known to humans, and effective treatment for BoNT intoxication is urgently needed. Single-domain antibodies (VHH) have been examined as a countermeasure for BoNT because of their high ...
Jin, Rongsheng, Lam, Kwok-Ho, McNutt, Patrick M, Ondeck, Celinia, Perry, Kay, Shoemaker, Charles B, Tremblay, Jacqueline M, Vazquez-Cintron, Edwin, Webb, Robert P   +8 more
core   +10 more sources

Development of an Innovative in Vitro Potency Assay for Anti-Botulinum Antitoxins [PDF]

Toxins, 2016
Botulinum neurotoxins are bacterial proteins that cause botulism, a life-threatening disease. Therapy relies mostly on post-intoxication antibody treatment. The only accepted method to measure the potency of, and to approve, antitoxin preparations is the mouse lethality neutralization bioassay.
Osnat Rosen, Eyal Ozeri, Ada Barnea, Alon David, Ran Zichel   +4 more
doaj   +6 more sources

Equine botulinum antitoxin for the treatment of infant botulism. [PDF]

Clin Vaccine Immunol, 2011
ABSTRACTInfant botulism is the most common form of human botulism in Argentina and the United States. BabyBIG (botulism immune globulin intravenous [human]) is the antitoxin of choice for specific treatment of infant botulism in the United States. However, its high cost limits its use in many countries.
Vanella de Cuetos EE, Fernandez RA, Bianco MI, Sartori OJ, Piovano ML, Lúquez C, de Jong LI.   +6 more
europepmc   +5 more sources

Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin. [PDF]

Clin Infect Dis, 2017
Botulism is a rare, life-threatening paralytic illness. Equine-derived heptavalent botulinum antitoxin (HBAT), the only currently available treatment for noninfant botulism in the United States, was licensed in 2013. No reports have systematically examined safety and clinical benefit of HBAT among botulism patients.From March 2010 through March 2013 ...
Yu PA, Lin NH, Mahon BE, Sobel J, Yu Y, Mody RK, Gu W, Clements J, Kim HJ, Rao AK.   +9 more
europepmc   +5 more sources

Iatrogenic Botulism After Cosmetic Use of Botulinum Toxin-A: A Case Series. [PDF]

Clin Case Rep
ABSTRACT Botulism symptoms after cosmetic botulinum toxin‐A (BTX‐A) injections happen very rarely, and it needs careful attention since it can be life‐threatening. Hence, it is advised to meticulously check the technique, dose, and authenticity of the BTX‐A before injections to reduce the adverse effects.
Asadi M, Shadnia S, Mostafazadeh B, Evini PET, Zandieh F, Rahimi M.   +5 more
europepmc   +2 more sources

New equine antitoxins to botulinum neurotoxins serotypes A and B [PDF]

Biologicals, 2012
Hyperimmune monovalent antitoxins to botulinum neurotoxin serotypes A and B have been produced by immunizing horses with newly developed formalin toxoids. After primary immunization, horses developed acceptable prophylactic antibody titers (1-5 IU/mL). Three horses received additional toxoid booster injections to induce hyperimmune antibody titers with
D. Li, P. Mattoo, J.E. Keller
openaire   +3 more sources

A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes. [PDF]

Toxins, 2018
Human botulism is most commonly caused by botulinum neurotoxin (BoNT) serotypes A, B, and E. For this work, we sought to develop a human monoclonal antibody (mAb)-based antitoxin capable of binding and neutralizing multiple subtypes of BoNT/E.
Brown, Jennifer L, Conrad, Fraser, Farr-Jones, Shauna, Garcia-Rodriguez, Consuelo, Geren, Isin N, Lou, Jianlong, Marks, James D, Razai, Ali, Skerry, Janet C, Smith, Leonard A, Smith, Theresa J, Wen, Wei-Hua   +11 more
core   +17 more sources

354 Case of infant botulism and review of the use of heptavalent botulinum antitoxin for treatment [PDF]

Abstracts, 2021
Background Infant botulism is a rare and potentially lethal condition resulting in symmetrical descending flaccid paralysis, caused by ingestion of Clostridium botulinum spores. Human Botulism Immune Globulin Intravenous (BIG-IV) is deemed safe and effective in reducing inpatient and intensive care unit (ICU) stay for infants with botulism.
Karen Donceras Nadua, Ann Chuan En Loh, Terrence Gerard Sundram Thomas, Matthias Maiwald, Xue Fen Valerie Seah, Natalie Woon Hui Tan   +5 more
openaire   +4 more sources

Intragastric Botulinum Toxin Injection and Botulism: An Alarm for Clinicians. [PDF]

Case Rep Crit Care
Clostridium botulinum produces the most potent bacterial toxin, botulinum toxin A (BTXA), which has various therapeutic and cosmetic indications. Intragastric BTXA injection is a new obesity treatment method that was argued to be safe due to the inactivation of BTXA through the liver or metabolization within the gastric wall.
Mojtahedzadeh M, Najmeddin F, Pourheidar E, Najafi A, Bahman R, Yousefi-Mazhin E, Karballaei-Mirzahosseini H, Hassanpour R.   +7 more
europepmc   +2 more sources

A systematic review of tea pigments: Prevention of major diseases, protection of organs, and potential mechanisms and applications

Food Science &Nutrition, Volume 11, Issue 11, Page 6830-6844, November 2023., 2023
Abstract With the growing awareness of a healthy life, tea pigments (TPGs) are in focus for their health benefits. TPGs not only provide specific color to tea liquor but also possess health benefits such as anti‐obesity, anti‐tumor, anti‐inflammatory, anti‐viral, anti‐oxidative, and bacteriostatic properties. Also, TPGs can benefit bone, liver, kidney,
Xuan Zhao, Fei Yan, Xin‐Sheng Li, Dong Qu, Yue‐Ling Xu   +4 more
wiley   +1 more source